

**Maryland Board of Pharmacy
Public Board Meeting**

**Meeting Minutes
Date: August 20, 2014**

Name	Title	Present	Absent	Present	Absent
Board Committee					
Ashby, D.	Commissioner	X		7	1
Bradley-Baker, L.	Commissioner/Secretary	X		8	0
Gavvani, M. Z.	Commissioner/Treasurer	X		7	1
Israbian-Jamgochian, L.	Commissioner/President	X		7	1
Jones, David H.	Commissioner	X		8	0
Peters, Roderick	Commissioner	X		3	0
Robinson, T.	Commissioner	X		7	1
Rochester, C.	Commissioner	X		8	0
Roy, S.	Commissioner	X		7	1
Smith, J.	Commissioner	X		7	1
St. Cyr, II, Z. W.	Commissioner	X		8	0
Zagnit, B.	Commissioner	X		7	1
Board Counsel					
Bethman, L.	Board Counsel	X		8	
Felter, B.	Staff Attorney	X		8	
Board Staff					
Naesea, L.	Executive Director		X	6	2(excused)
Wu, Y.	Compliance Manager		X	6	2(excused)
Waddell, L.	Licensing Manager		X	6	2(excused)
Gaither, P.	Administration and Public Support Manager	X		6	2(excused)
Jeffers, A.	Legislation/Regulations Manager	X		8	0
Johnson, J.	MIS Manager	X		7	1(excused)

Subject	Responsible Party	Discussion	Action Due Date (Assigned To)	Results
I. Executive Committee Report(s)	<p>A.) L. Israbian-Jamgochian, Board President</p> <p>B.) L. Bradley-Baker, Secretary</p>	<p><i>Members of the Board with a conflict of interest relating to any item on the agenda are advised to notify the Board at this time or when the issue is addressed in the agenda.</i></p> <ol style="list-style-type: none"> 1. L. Israbian-Jamgochian called the meeting to order at 9:39 a.m. 2. L. Israbian-Jamgochian reminded all guests to sign the guest log, indicating whether they would like continuing education credits. 3. L. Israbian-Jamgochian requested that all guests introduce themselves and also informed them that the meeting agenda and packet materials were available for review. She advised them that all packets must be returned at the end of the meeting. 4. Review and approval of July 2014 Minutes 	<p>4. Amendments to July 2014 minutes requested by D Jones as follows: Section III-C Public Relations D Jones is listed as D Jones II, and annual meeting should read ASCP</p> <p>Motion to approve with amendments by M. Gavgani 2nd by S. Roy</p>	<p>4. The Board voted to approve the motion.</p>
II. A. Executive Director Report	L. Naesea, Executive Director	<p><i>This section was presented by Patricia Gaither in the absence of LaVerne Naesea</i></p> <ol style="list-style-type: none"> 1. Operations Updates: <p>There is a proposal in place for the new office</p>		

Subject	Responsible Party	Discussion	Action Due Date (Assigned To)	Results
		<p>furniture and equipment for the move to the 5th floor. The move is scheduled to take place in October.</p> <p>2. Meetings Updates: Two meetings took place on August 8, 2014, the first for the new MIS system and the second for the new Reorganization plan. During the MIS meeting, which included Phil Helmer, Director of OIT and Queen Davis, Procurement Officer various options were discussed regarding soliciting vendors. During the meeting with the DHMH Human Resources Director and key staff, the plan for reorganization was supported and approved to submit to DBM for final approval.</p> <p>3. Media Inquiry/Response on Prescription Pad Theft (attachment)</p> <p>4. NABP/Maryland Verified Pharmacy MOU (attachment)</p> <p>L. Bethman gave an overview and brief description of the MOU.</p>	<p>4. Motion to approve by M. Gavgani, 2nd by D Jones.</p>	<p>4. The Board voted to approve the motion.</p>
<p>B. Administration and Public Support (APS)</p>	<p>B. P. Gaither, APS Manager</p>	<p>1. Personnel Updates –</p> <p>The vacancy for an Inspector in the Compliance unit has been filled. The candidate for the licensing secretary has been appointed. Peer reviewer contract for R Zimmer has been completed and is ready for review by L. Bethman.</p>		

Subject	Responsible Party	Discussion	Action Due Date (Assigned To)	Results
		<p>The Database Specialist position is currently vacant in the MIS unit. The recruitment for a half-time Pharmacist Inspector position is currently underway. The contractual positions for the Health Occupations Investigator and Office Clerk will be converted to permanent positions. Recruitment for the Health Occupations Investigator, will begin immediately. The selected Lab scientist candidate declined the offer because she was accepted a position with another company.</p> <p>2. Contracts and Procurement</p> <p>Furniture for the office's move to the 5th floor will be purchased. The PEAC contract will be approved on August 20, 2014. The Mobile Inspection Unit contract is progressing with the assignment for a contract officer from DHMH.</p> <p>FY 2014 Budget Summary: \$ 3.3 million was the total budget allocation for fiscal year 2014, which included an increase approved later in the fiscal year. The total funds expended was \$2.7 million and the carry over balance was \$565 thousand.</p>		
C. MIS	J. Johnson, MIS Manager	<p>1. MIS Update</p> <p>The Scanning project is currently far below the projected total cost. MIS and APS units are beginning processes to send documents that have been scanned to state archives.</p>		

Subject	Responsible Party	Discussion	Action Due Date (Assigned To)	Results																					
		<p>J. Johnson is eager to begin recruitment for the new MIS vacancy. The Mobile Inspection program will be going up for bid. J. Johnson and L. Naesea met with DHMH OIT for new database. With the new OIT program, DOIT will approve a contractor to do market research to find the best company to complete the program.</p>																							
D. Licensing	L. Waddell, Licensing Manager	<p><i>The Information in this section was presented by Tiffany Duncan in the absence of Latoya Waddell.</i></p> <p>1. Unit Updates None at this time.</p> <p>2. Monthly Statistics</p> <p><i>July 2014 data</i></p> <table border="1" data-bbox="548 878 1220 1219"> <thead> <tr> <th><u>License Type</u></th> <th><u>New/Renewed</u></th> <th><u>Total</u></th> </tr> </thead> <tbody> <tr> <td>Pharmacist</td> <td>203/340</td> <td>10,263</td> </tr> <tr> <td>Pharmacy Tech</td> <td>110/294</td> <td>8,828</td> </tr> <tr> <td>Student Tech</td> <td>20/0</td> <td>863</td> </tr> <tr> <td>Pharmacy</td> <td>22/6</td> <td>1,898</td> </tr> <tr> <td>Distributor</td> <td>9/1</td> <td>1,041</td> </tr> <tr> <td>Vaccines</td> <td>82/16</td> <td>3,710</td> </tr> </tbody> </table>	<u>License Type</u>	<u>New/Renewed</u>	<u>Total</u>	Pharmacist	203/340	10,263	Pharmacy Tech	110/294	8,828	Student Tech	20/0	863	Pharmacy	22/6	1,898	Distributor	9/1	1,041	Vaccines	82/16	3,710		
<u>License Type</u>	<u>New/Renewed</u>	<u>Total</u>																							
Pharmacist	203/340	10,263																							
Pharmacy Tech	110/294	8,828																							
Student Tech	20/0	863																							
Pharmacy	22/6	1,898																							
Distributor	9/1	1,041																							
Vaccines	82/16	3,710																							
E. Compliance	Y. Wu, Compliance Manager	<p><i>The information in this section was presented by Nicole Bennett-Kerr in the absence of YuZon Wu.</i></p> <p>1. Unit Updates</p>																							

Subject	Responsible Party	Discussion	Action Due Date (Assigned To)	Results
		<p>None at this time</p> <p>2. Monthly Statistics</p> <p>Complaints & Investigations:</p> <p>New Complaints 55 Resolved (Including Carryover) 26 Final disciplinary actions taken 6 Reversals 0 Summary Actions Taken 0</p> <p>Inspections:</p> <p>Total (includes re-inspections) 113* Annual Inspections 98 Opening Inspections 6 Closing Inspections 1 Relocation Inspections 3 Board Special Investigation Inspections 5 Division of Drug Control Closing Inspections 4</p> <p>PEAC Update</p> <p>Total Rehabilitation Clients (PEAC) – 18 Pharmacist – 15 Technician – 2 Pharmacy Student – 0 Clients Monitored by Board Req. PEAC Assistance – 1</p> <p>Drug Test Results - 14 Number of Positive Results-0</p> <p>Discharged Clients/Closed Cases- 0</p>		

Subject	Responsible Party	Discussion	Action Due Date (Assigned To)	Results
<p>F. Legislation & Regulations</p>	<p>A. Jeffers, Legislation & Regulations Manager</p>	<p><u>REGULATIONS:</u></p> <p><u>10.34.19 Sterile Pharmaceutical Compounding and 10.34.09 Fees</u></p> <p>Notice of Final Action published on June 27, 2014 with an Effective Date of January 1, 2015.</p> <p>Sterile Compounding Committee continuing to meet regarding implementation. Next meeting 8/25</p> <p>Sterile Compounding Survey went live on the website on July 21st. Blast email sent shortly thereafter with a September 1, 2014 deadline for responses.</p> <p>FAQs went on the website July 31, 2014.</p> <p>Meeting with Dental Board representatives scheduled for August 27th.</p> <p>Anna reported that NABP will respond in the next few days regarding how 503B facilities, Outsourcing Facilities, will acquire VAWD accreditation to obtain a wholesale distributor permit in MD.</p> <p><u>10.34.38 Pharmacy Interns</u></p> <p>Board released proposed regulations for informal comment until August 15th. Responses to be discussed at the August Practice Committee Meeting.</p> <p><u>10.13.01 Dispensing of Prescription Drugs by a Licensee</u></p> <p>Proposal published May 30, 2014. Placed on HOLD by AELR.</p>	<p><u>10.34.38 Pharmacy Interns</u> Anna has only received 3 comments so far.</p>	

Subject	Responsible Party	Discussion	Action Due Date (Assigned To)	Results
		<p>All required responses submitted to DHMH Regulations Office on July 17, 2014.</p> <p><u>LEGISLATION:</u></p> <p>1) Nurses Dispensing at Local Health Departments</p> <p>The Board discussed and approved the most recent revisions. These revisions consisted of:</p> <p>§ 3-401.</p> <p>A. THERE SHALL BE AN APPROVED FORMULARY FOR DISPENSING BY LICENSED REGISTERED NURSES IN LOCAL HEALTH DEPARTMENTS FOR THE TREATMENT OF PATIENTS IN NEED OF COMMUNICABLE DISEASE, ALCOHOL AND DRUG ABUSE, AND FAMILY PLANNING AND REPRODUCTIVE HEALTH SERVICES.</p> <p>§3-402.</p> <p>A. THE DEPARTMENT SHALL ESTABLISH A COMMITTEE FOR APPROVING A FORMULARY FOR DISPENSING BY LICENSED REGISTERED NURSES IN LOCAL HEALTH DEPARTMENTS.</p>	<p>Motion to approve changes by D Jones, 2nd by M. Gavvani</p>	<p>The Board voted to approve the motion.</p>

Subject	Responsible Party	Discussion	Action Due Date (Assigned To)	Results
		<p>B. THE COMMITTEE MEMBERSHIP SHALL INCLUDE:</p> <p>(1) A REPRESENTATIVE FROM THE DEPARTMENT;</p> <p>(2) A REPRESENTATIVE FROM THE BOARD OF NURSING;</p> <p>(3) A REPRESENTATIVE FROM THE BOARD OF PHARMACY;</p> <p>(4) A PHARMACIST FROM THE COMMUNITY;</p> <p>(5) A REPRESENTATIVE FROM THE MARYLAND COUNCIL OF PUBLIC HEALTH NURSE DIRECTORS;</p> <p>(6) A REPRESENTATIVE FROM THE DIVISION OF DRUG CONTROL;</p> <p>(7) A REPRESENTATIVE FROM THE BOARD OF PHYSICIANS; AND</p> <p>(8) A REPRESENTATIVE FROM THE LOCAL HEALTH DEPARTMENTS.</p> <p>§3-403. THE FORMULARY SHALL BE REVIEWED</p>		

Subject	Responsible Party	Discussion	Action Due Date (Assigned To)	Results
		<p>PERIODICALLY TO ENSURE CURRENCY.</p> <p>§3-404. NO FEE SHALL BE CHARGED FOR DISPENSING IN A LOCAL HEALTH DEPARTMENT.</p> <p>§3-405. A LOCAL HEALTH DEPARTMENT THAT DISPENSES DRUGS AND DEVICES IN ACCORDANCE WITH §3-401 OF THIS ARTICLE SHALL BE SUBJECT TO INSPECTION BY THE DEPARTMENT. AND REGULATION BY THE DIVISION OF DRUG CONTROL.</p> <p>§3-406. THE DEPARTMENT SHALL ESTABLISH A TRAINING PROGRAM FOR LICENSED REGISTERED NURSES DISPENSING IN A LOCAL HEALTH DEPARTMENT IN ACCORDANCE WITH HEALTH OCCUPATIONS ARTICLE, TITLE 12 AND §8-512, ANNOTATED CODE OF MARYLAND.</p> <p style="text-align: center;">Article – Health Occupations</p> <p>§8-512.</p> <p style="padding-left: 40px;">(A) IN THIS SECTION THE FOLLOWING WORDS HAVE THE MEANINGS INDICATED.</p> <p style="padding-left: 80px;">(1) “AUTHORIZED PRESCRIBER” MEANS</p>		

Subject	Responsible Party	Discussion	Action Due Date (Assigned To)	Results
		<p>ANY LICENSED ADVANCED PRACTICE REGISTERED NURSE, LICENSED DENTIST, LICENSED PHYSICIAN, LICENSED PHYSICIAN'S ASSISTANT, LICENSED PODIATRIST OR OTHER INDIVIDUAL AUTHORIZED BY LAW TO PRESCRIBE PRESCRIPTION OR NONPRESCRIPTION DRUGS OR DEVICES WHO IS EMPLOYED BY A LOCAL HEALTH DEPARTMENT.</p> <p>(2) (A) "DEVICE" MEANS A DEVICE USED IN THE DIAGNOSIS, TREATMENT, OR PREVENTION OF DISEASE.</p> <p>(3) "DEVICE" DOES NOT INCLUDE ANY:</p> <p>(A) SURGICAL OR DENTAL INSTRUMENT;</p> <p>(B) PHYSICAL THERAPY EQUIPMENT;</p> <p>(C) X-RAY APPARATUS; OR</p> <p>(D) A COMPONENT PART OR ACCESSORY OF ANY OF THESE ITEMS.</p>		

Subject	Responsible Party	Discussion	Action Due Date (Assigned To)	Results
		<p>(4) "DISPENSE" MEANS THE PROCEDURE RESULTING IN RECEIPT OF A PRESCRIPTION OR NONPRESCRIPTION DRUG OR DEVICE BY A CLIENT PATIENT OR A CLIENT'S PATIENT'S AGENT WHICH INCLUDES:</p> <p style="padding-left: 40px;">(A) INTERPRETING AN AUTHORIZED PRESCRIBER'S PRESCRIPTION FOR A DRUG OR DEVICE;</p> <p style="padding-left: 40px;">(B) SELECTING AND LABELING OF THE DRUG OR DEVICE PRESCRIBED;</p> <p style="padding-left: 40px;">(C) MEASURING AND PACKAGING OF THE DEVICE IN ACCORDANCE WITH THE LAWS OF THIS STATE AND THE FEDERAL GOVERNMENT;</p> <p>AND</p> <p style="padding-left: 40px;">(D) DOCUMENTING THE TRANSACTION IN THE CLIENT'S PATIENT'S MEDICAL RECORD.</p> <p>(5) "NON PRESCRIPTION DRUG" MEANS A DRUG WHICH MAY BE SOLD WITHOUT A</p>		

Subject	Responsible Party	Discussion	Action Due Date (Assigned To)	Results
		<p>PRESCRIPTION AND WHICH IS LABELED FOR USE BY A CONSUMER IN ACCORDANCE WITH THE LAWS AND REGULATIONS OF THIS STATE AND THE FEDERAL GOVERNMENT.</p> <p>(6) “ PERSONALLY PREPARE AND DISPENSE” MEANS THE LICENSED REGISTERED NURSE WHO HAS BEEN APPROVED FOR DISPENSING DRUGS AND DEVICES AS PART OF HIS OR HER DUTIES IN A LOCAL HEALTH DEPARTMENT:</p> <p>(A) IS PHYSICALLY PRESENT ON THE PREMISES WHERE PREPARES THE PRESCRIPTION IS FILLED; AND</p> <p>(B) PERFORMS A FINAL CHECK OF THE PRESCRIPTION BEFORE DISPENSING IT IS PROVIDED TO THE PATIENT; AND</p> <p>(C) MAY NOT DELEGATE ANY STEP OF THE DISPENSING PROCESS.</p> <p>B. A LICENSED REGISTERED NURSE, EMPLOYED BY A LOCAL HEALTH DEPARTMENT, MAY</p>		

Subject	Responsible Party	Discussion	Action Due Date (Assigned To)	Results
		<p>PERSONALLY PREPARE AND DISPENSE PRESCRIPTION OR NON PRESCRIPTION DRUGS OR DEVICES FOR THE TREATMENT OF PATIENTS IN NEED OF COMMUNICABLE DISEASE, ALCOHOL AND DRUG ABUSE, AND FAMILY PLANNING AND REPRODUCTIVE HEALTH SERVICES SUBJECT TO THE FOLLOWING REQUIREMENTS;</p> <p>(1) THE DRUGS OR DEVICES ARE ON A FORMULARY APPROVED JOINTLY BY:</p> <p style="padding-left: 40px;">(A) THE BOARD;</p> <p>_____ (B) THE BOARD OF PHARMACY;</p> <p>_____ (C) THE BOARD OF PHYSICIANS; AND</p> <p>_____ (D) THE DEPARTMENT;</p> <p style="padding-left: 40px;">(A) A REPRESENTATIVE FROM THE DEPARTMENT;</p> <p style="padding-left: 40px;">(B) A REPRESENTATIVE FROM THE BOARD;</p>		

Subject	Responsible Party	Discussion	Action Due Date (Assigned To)	Results
		<p>(C) A REPRESENTATIVE FROM THE BOARD OF PHARMACY;</p> <p>(D) A PHARMACIST FROM THE COMMUNITY;</p> <p>(E) A REPRESENTATIVE FROM THE MARYLAND COUNCIL OF PUBLIC HEALTH NURSE DIRECTORS;</p> <p>(F) A REPRESENTATIVE FROM THE DIVISION OF DRUG CONTROL;</p> <p>(G) A REPRESENTATIVE FROM THE BOARD OF PHYSICIANS;</p> <p>AND</p> <p>(H) A REPRESENTATIVE FROM THE LOCAL HEALTH DEPARTMENTS.</p> <p>(2) THE LICENSED REGISTERED NURSE HAS SUCCESSFULLY COMPLETED THE DEPARTMENT'S APPROVED TRAINING PROGRAM</p>		

Subject	Responsible Party	Discussion	Action Due Date (Assigned To)	Results
		<p>FOR DISPENSING DRUGS OR DEVICES; AND</p> <p>(3) THE LICENSED REGISTERED NURSE SHALL:</p> <p>(A) SHALL MAINTAIN THE CLIENT'S PATIENT'S HEALTH RECORD AND FILES IN A MANNER THAT ENSURES THE CONFIDENTIALITY OF THE CLIENT'S PATIENT'S DRUG AND DEVICE ADMINISTRATION MEDICATION RECORD IN ACCORDANCE WITH STATE AND FEDERAL LAWS;</p> <p>(B) SHALL COMPLY WITH DRUG AND DEVICE STORAGE AND INVENTORY PROCEDURES IN ACCORDANCE WITH DEPARTMENT POLICY; AND</p> <p>(C) DEMONSTRATE AN ADHERENCE TO BEST PRACTICES INCLUDING, BUT NOT LIMITED TO, REFUSING MAY REFUSE TO DISPENSE A DRUG OR DEVICE THAT MIGHT CAUSE CLIENT PATIENT HARM; AND</p>		

Subject	Responsible Party	Discussion	Action Due Date (Assigned To)	Results
		<p>(4) THE LICENSED REGISTERED NURSE HAS RECEIVED A PRESCRIPTION FROM AN AUTHORIZED PRESCRIBER EMPLOYED AT THE LOCAL HEALTH DEPARTMENT.</p> <p>(C) THE TRAINING PROGRAM FOR LICENSED REGISTERED NURSES DISPENSING IN LOCAL HEALTH DEPARTMENTS SHALL BE:</p> <p>(1) SUCCESSFULLY COMPLETED BY ANY LICENSED REGISTERED NURSE PRIOR TO THEIR BEFORE DISPENSING ANY MEDICATION OR DEVICE IN A LOCAL HEALTH DEPARTMENT;</p> <p>(2) ADMINISTERED BY THE DEPARTMENT OR ITS DESIGNEE;</p> <p>(3) JOINTLY DEVELOPED BY:</p> <p>(A) THE BOARD;</p> <p>(B) THE BOARD OF PHARMACY; AND</p> <p>(C) THE DEPARTMENT; AND</p> <p>(4) PERIODICALLY REVIEWED TO</p>		

Subject	Responsible Party	Discussion	Action Due Date (Assigned To)	Results
		<p>ENSURE CURRENCY.</p> <p>EPT Legislation: The review of the most recent draft bill was referred to the Practice Committee.</p> <p><u>OTHER MATTERS:</u></p> <p>None at this time</p>		
<p>III. Committee Reports A. Practice Committee</p>	<p>M. Gavgani, Chair</p>	<p><u>Inquiries:</u></p> <p>1. Monica Pogue, Walgreens</p> <p><u>Zostavax age issue</u></p> <p><u>Draft Bd Response - Zostavax Age Issue</u></p> <p>Thank you for contacting the Maryland Board of Pharmacy concerning at what age the Zostavax vaccine may be administered to adults. Zostavax has been approved by the FDA for patient 50 or older. It is recommended by the CDC for patient 60 and older. If a doctor writes a prescription for a specific patient for Zostavax, and they are between the ages of 50 and 59, are we permitted to administer the vaccine?</p> <p>A pharmacist may administer Zostavax to a patient between the ages of 50 and 59 pursuant to a</p>	<p>1. Motion to approve response as prepared by Practice Committee, 2nd by D. Ashby.</p>	<p>1. The Board voted to approve.</p>

Subject	Responsible Party	Discussion	Action Due Date (Assigned To)	Results
		<p>prescription because it is listed in the Centers for Disease Control and Prevention’s (CDC) recommended immunization schedule for adults. See Health Occupations Article, 12-508, Annotated Code of Maryland. A vaccine specific protocol is required. See also the CDC’s recommendations for Zoster.</p> <p style="text-align: center;">Zoster vaccination</p> <ul style="list-style-type: none"> • A single dose of zoster vaccine is recommended for adults aged 60 years or older regardless of whether they report a prior episode of herpes zoster. Although the vaccine is licensed by the U.S. Food and Drug Administration for use among and can be administered to persons aged 50 years or older, ACIP recommends that vaccination begin at age 60 years. • Persons aged 60 years or older with chronic medical conditions may be vaccinated unless their condition constitutes a contraindication, such as pregnancy or severe immunodeficiencyⁱ <p>2. Danielle Austin, Peninsula Regional Medical Center</p> <p><u>Remote verification</u></p> <p><u>Draft Bd Response - remote verification</u></p> <p>Thank you for contacting the Maryland Board of Pharmacy concerning whether the Maryland Pharmacy Act would allow remote verification by</p>	<p>2. Motion to approve response as prepared by Practice Committee with a suggestion by L. Bethman to soften the letter language, 2nd by M. Gavgani. Discussion ensued regarding the Board’s future consideration of emerging technology such as video monitoring.</p>	<p>2. The Board voted to approve with suggestions made by L. Bethman.</p>

Subject	Responsible Party	Discussion	Action Due Date (Assigned To)	Results
		<p>camera by a pharmacist trained in the compounding of chemo medications when the compounding of chemo medications is performed by a pharmacy technician at a different licensed pharmacy where the designated pharmacist is not trained in the compounding of chemo medications.</p> <p>Please be advised that a pharmacist utilizing video remote verification of pharmacy technicians compounding chemo medications at another pharmacy does not fall within direct supervision. The pharmacist must be on site in the production area to perform the verification of the sterile compounding of chemo medications. See the Code of Maryland Regulations (COMAR) 10.34.34.02B(4) and .03A(8).</p> <p>The Maryland Pharmacy Act requires direct supervision of delegated pharmacy acts. Md. Code Ann., Health Occ. § 12-101(g). Thus, registered pharmacy technicians performing delegated pharmacy acts must be directly supervised by a pharmacist. At the present time, the Board defines direct supervision to mean “physically available onsite.” As technology changes and the practice of pharmacy changes with it, the Board may revisit video, and other emerging technologies, in the next few years. Having stated that, the Board recognizes that a supervising pharmacist may step outside the pharmacy temporarily to use the restroom or have a break. Again, a pharmacist should always exercise sound professional judgment and ensure</p>		

Subject	Responsible Party	Discussion	Action Due Date (Assigned To)	Results
		that pharmacy technicians are able to immediately consult with the pharmacist, if necessary, during his or her brief absence.		
B. Licensing Committee	L. Bradley-Baker, Chair	<p>1. Review of Pharmacist Applications:</p> <p>A. Jenkaa Dzekashu -Would like a duplicate license without paying fee. Licensing Committee recommendation is to deny request.</p> <p>B. Olufunke Sokan-Requesting to renew license earlier than the usual 45 days due to sponsorship for VISA. Licensing Committee recommendation is to deny request.</p> <p>C. Ehab Ammar - Applicant went to Ohio University and would like the Board to accept his education to become a licensed MD pharmacist. Licensing Committee recommendation is to deny request and inform applicant of the requirements of a foreign graduate to be licensed in MD.</p> <p>D. Steven Brown- Would like a refund of application fee. Licensing Committee recommendation is to deny request.</p> <p>E. Nuri Tawwab -Requesting Board to accept expired NAPLEX score due to remote area of residence. Licensing Committee recommendation is to grant extension for 90 days from 08/20.</p>	<p>A. Motion to deny the request by committee, 2nd by D. Jones.</p> <p>B. Motion to deny the request by committee, 2nd by D. Ashby.</p> <p>C. Motion to deny the request and inform applicant of proper requirements by committee, 2nd by J. Smith.</p> <p>D. Motion to deny the request, 2nd by S. Roy.</p> <p>E. Motion to grant extension by committee, 2nd by D. Jones.</p>	<p>A. The Board voted to approve the motion.</p> <p>B. The Board voted to approve the motion. C. Rochester recused.</p> <p>C. The Board voted to approve the motion.</p> <p>D. The Board voted to approve the motion.</p> <p>E. The Board voted to approve the motion.</p> <p>F. The Board voted to</p>

Subject	Responsible Party	Discussion	Action Due Date (Assigned To)	Results
		<p>F. Tahani Wanis -Would like Board to waive FPGEC requirement. Licensing Committee recommendation is to deny request.</p> <p>2. Review of Pharmacy Technician Applications: None</p> <p>3. Review of Distributor Applications: None</p> <p>4. Review of Pharmacy Applications:</p> <p>RxCare Providers- Would like a refund of reinstatement fees</p> <p>5. Review of Pharmacy Technicians Training Programs:</p> <p>A. Fortis Institute - (Modification of two courses) - Licensing Committee recommendation is to approve.</p> <p>B. New Albertson's Inc. and SUPERVALU Pharmacies - Licensing Committee recommendation is to approve.</p> <p>6. New Business:</p> <p>A. Christine Cohn -Would like to know if MD prohibits physician ownership of a MD licensed pharmacy. Licensing Committee recommendation is to inform pharmacist that MD does prohibit</p>	<p>F. Motion to deny the request by committee, 2nd by C. Rochester.</p> <p>4. Motion to deny the request by committee, 2nd by D. Ashby.</p> <p>A. Motion to approve training program by committee, 2nd by J. Smith.</p> <p>B. Motion to approve training program by committee, 2nd by Z. St. Cyr, II.</p> <p>A. Motion to inform Dr. Cohn MD law regarding this issue, 2nd by M. Gavgani.</p>	<p>approve the motion.</p> <p>4. The Board voted to approve the motion.</p> <p>A. The Board voted to approve the motion.</p> <p>B. The Board voted to approve the motion.</p> <p>A. The Board voted to approve the motion.</p>

Subject	Responsible Party	Discussion	Action Due Date (Assigned To)	Results
		<p>ownership.</p> <p>B. MD Licensed Pharmacist Form -Board to approve new form for nonresidential pharmacies. Licensing Committee recommendation is to approve.</p> <p>C. Release of ACPE Guidelines - FYI- Information on the new guidelines on Continuing Education Credits.</p> <p>D. Sterile Compounding Permit and Waiver Application- Licensing Committee has reviewed and approved.</p>	<p>B. Motion to approve new form for nonresidential pharmacies, 2nd by M. Gavvani.</p> <p>D. Motion to approve application, 2nd by M. Gavvani.</p>	<p>B. The Board voted to approve the motion.</p> <p>D. The Board voted to approve the motion.</p>
C. Public Relations Committee	D. Jones, Chair	<p>Public Relations Committee Update:</p> <p><i>Because of a presentation of invited guests this section was presented directly after Section I, Executive Committee Reports.</i></p> <p>D Jones presented an overview of the successful Maryland ASCP meeting, provided additional information on the next two upcoming board events: the Continuing Education (CE) brunch and the Baby Boomers Expo.</p> <p><i>Guest Speaker Dr. Kristaps Paddock, Naturopathic Formulary Doctor</i></p>		
D. Disciplinary	M, Gavvani, Chair	<p>Disciplinary Committee Update</p> <p>None</p>		

Subject	Responsible Party	Discussion	Action Due Date (Assigned To)	Results
E. Emergency Preparedness Task Force	S. Roy, Chair	Emergency Preparedness Task Force Update None		
IV. Other Business & FYI	L. Israbian-Jamgochian, Board President			
V. Adjournment	L. Israbian-Jamgochian, Board President	<p>The Public Meeting was adjourned at 11:14.</p> <p>At 11:30 A.M. L. Israbian-Jamgochian convened a Closed Public Session with a presentation from representatives from the University of Maryland School of Pharmacy regarding challenges their students are facing with the Maryland Jurisprudence Exam (MPJE) and also to conduct a medical review of technician applications.</p> <p>C. The Closed Public Session was adjourned at _____ P.M. Immediately thereafter, L. Israbian-Jamgochian convened an Administrative Session for purposes of discussing confidential disciplinary cases. With the exception of cases requiring recusals, the Board members present at the Public Meeting continued to participate in the Administrative Session.</p>	Motion to close the meeting by D. Jones, 2 nd by B. Zagnit.	The Board voted to approve the motion.

ⁱ <http://www.cdc.gov/vaccines/schedules/hcp/imz/adult.html>